基于超声检测观察麝香保心丸治疗冠心病心绞痛的临床研究

Clinical observation on angina pectoris of coronary heart disease based on ultrasonic examination with Shexiang Baoxin Pills

目的观察麝香保心丸治疗冠心病心绞痛对患者超声心动图指标的影响。方法选取2014年1月至2016年12月收治的80例冠心病心绞痛患者采用随机数字表法分为对照组和麝香保心丸组各40例。对照组采用西医常规治疗,包括抗血小板聚集药、调脂药、扩冠治疗等;麝香保心丸组在西医常规治疗的基础上联合应用麝香保心丸,口服3粒/次,3次/d,连续治疗8周为1个疗程。采用超声心动图检测两组患者左室收缩末期容积(LVESV)、左室舒张末期容积(LVEDV)、左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)、心脏指数(CI)、心输出量(CO)、左室射血分数(LVEF)。观察两组治疗前后血脂TG、TC、HDL-C、LDL-C指标水平的变化。结果治疗后麝香保心丸组总有效率为90.0%,高于对照组的72.5%,差异有统计学意义(P<0.05)。治疗后两组LVEF均较治疗前明显上升,差异有统计学意义(P<0.05),且麝香保心丸组显著高于对照组,两组比较差异有统计学意义(P<0.05);治疗后两组LVESV、LVESD、LVEDV、LVEDD均较治疗前明显下降,差异有统计学意义(P<0.05),且麝香保心丸组明显低于对照组,两组比较差异有统计学意义(P<0.05)。治疗后两组CO、CI较治疗前明显改善,差异有统计学意义(P<0.05),且麝香保心丸组改善程度优于对照组,两组比较差异有统计学意义(P<0.05)。治疗后两组患者TC、TG、LDL-C均下降与治疗前比较,差异有统计学意义(P<0.05);且麝香保心丸组TC、TG、LDL-C低于对照组,两组比较差异有统计学意义(P<0.05)。结论麝香保心丸治疗冠心病心绞痛疗效显著,能够明显改善超声心动图指标,提高临床疗效。

Objective To observe the effect of echocardiographic indexes in patients with angina pectoris of coronary heart disease treated with Shexiang Baoxin Pill. Methods 80 patients with angina pectoris from January 2014 to December 2016 were randomly divided into control group and Shexiang Baoxin Pill group with 40 cases in each group. The control group was treated with routine western medicine,including anti-platelet aggregation drugs,lipid-lowering drugs,crown-expanding therapy,etc. The Shexiang Baoxin pill group was treated with Shexiang Baoxin Pill on the basis of routine western medicine,oral 3 capsules per time,3 times per day,for 8 weeks as a course of treatment. Left ventricular end systolic volume（LVESV）,left ventricular end diastolic volume（LVEDV）,left ventricular end systolic diameter（LVESD）,left ventricular end diastolic diameter（LVEDD）,cardiac index（CI）,cardiac output（CO）,left ventricular ejection fraction（LVEF） were measured by echocardiography. The changes of serum TG,TC,HDL-C and LDL-C levels were observed before and after treatment in the two groups. Results After treatment,the total effective rate of Shexiang Baoxin Pill group was 90. 0%,which was higher than 72. 5% of the control group（P〈0. 05）. After treatment,the LVEF of the two groups was increased significantly（P〈0. 05）,and the Shexiang Baoxin Pill group was significantly higher than the control group.The difference was statistically significant（P〈0. 05）. The LVESV,LVESD,LVEDV,LVEDD of the two groups were significantly lower than before treatment（P〈0. 05）. The Shexiang Baoxin Pill group was significantly lower than the control group and the difference between the two groups was statistically significant（P〈0. 05）. After treatment,CO and CI of the two groups were significantly improved（P〈0. 05）,and the improvement degree of Shexiang Baoxin Pill group was better than that of the control group（P〈0. 05）. After treatment,TC,TG,LDL-C of the two groups were decreased compared with those before treatment（P〈0. 05）; and the TC,TG,LDL-C of the Shexiang Baoxin Pill group were lower than those of the control group（P〈0. 05）. Conclusion Shexiang Baoxin Pill is effective in treating angina pectoris of coronary heart disease. It could obviously improve echocardiographic indexes and clinical efficacy.